Mesenchymal Stem Cells Pretreated with HGF and FGF4 Can Reduce Liver Fibrosis in Mice

<div>(a) Expression of hepatic markers: (A1) RT-PCR analysis of MSCs pretreated with cytokines (Lanes 1–5) 0, 7, 15, 21, and 28 days for the expression of<i> Albumin</i>,<i> Cyt-8, and Cyt-18</i>. (Lane 6), mature hepatocytes were used as positive control. (A2) Gel band quantification by Image J software. (b) Immunocytochemistry of cytokines pretreated MSCs. (A–D) Expression of hepatic markers at protein level for<i> Albumin</i>, Cytokeratin 8, Cytokeratin 18, and AFP on day 15, respectively. Nuclei were counterstained with DAPI (blue) (200x, scale bar ~100 <i>μ</i>m). (c) PAS staining after pretreatment for glycogen storage: (A, B, C) PAS staining of cytokines pretreated MSCs on days 0, 15, and 21. (D) Mature hepatocytes as positive control (200x, scale bar ~100 <i>μ</i>m).</div>

Stem Cells International

fig2

Figure 2

Figure 2: Mesenchymal Stem Cells Pretreated with HGF and FGF4 Can Reduce Liver Fibrosis in Mice 